These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34081617)

  • 21. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
    Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
    Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender and age in the biochemical assessment of cure of acromegaly.
    Freda PU; Landman RE; Sundeen RE; Post KD
    Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.
    Barrande G; Pittino-Lungo M; Coste J; Ponvert D; Bertagna X; Luton JP; Bertherat J
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3779-85. PubMed ID: 11061538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remission criteria for the follow-up of patients with acromegaly.
    Gullu S; Keles H; Delibasi T; Tonyukuk V; Kamel N; Erdogan G
    Eur J Endocrinol; 2004 Apr; 150(4):465-71. PubMed ID: 15080775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender- and age-related differences in the endocrine parameters of acromegaly.
    Colao A; Amato G; Pedroncelli AM; Baldelli R; Grottoli S; Gasco V; Petretta M; Carella C; Pagani G; Tambura G; Lombardi G
    J Endocrinol Invest; 2002 Jun; 25(6):532-8. PubMed ID: 12109625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone.
    Subbarayan SK; Fleseriu M; Gordon MB; Brzana JA; Kennedy L; Faiman C; Hatipoglu BA; Prayson RA; Delashaw JB; Weil RJ; Hamrahian AH
    Endocr Pract; 2012; 18(6):817-25. PubMed ID: 22784832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly.
    Shen M; Chen Z; Shou X; He W; Qiao N; Ma Z; Ye Z; Zhang Y; Zhang Q; Zhou X; Cao X; Zhang Z; Ye H; Li Y; Zhao Y; Li S; He M; Wang Y
    J Neuroendocrinol; 2021 May; 33(5):e12958. PubMed ID: 33998086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F; Resmini E; Boschetti M; Arvigo M; Sormani MP; Giusti M; Ferone D; Barreca A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of IGF binding protein-3 as a parameter of activity in acromegalic patients.
    Halperin I; Casamitjana R; Flores L; Fernandez-Balsells M; Vilardell E
    Eur J Endocrinol; 1999 Aug; 141(2):145-8. PubMed ID: 10427158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
    De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
    Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
    Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
    Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
    J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
    Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.
    Reimondo G; Bondanelli M; Ambrosio MR; Grimaldi F; Zaggia B; Zatelli MC; Allasino B; Laino F; Aroasio E; Termine A; Conton P; Paoletta A; Demenis E; Uberti ED; Terzolo M
    Endocrine; 2014 Feb; 45(1):122-7. PubMed ID: 23794116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Characteristics of Acromegalic Patients With Paradoxical GH Response to Oral Glucose Load.
    Mukai K; Otsuki M; Tamada D; Kitamura T; Hayashi R; Saiki A; Goto Y; Arita H; Oshino S; Morii E; Saitoh Y; Shimomura I
    J Clin Endocrinol Metab; 2019 May; 104(5):1637-1644. PubMed ID: 30476255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.